-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Gardiquimod
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1020412-43-4.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1020412-43-4 |
| Description | Gardiquimod is a small-molecule agonist of TLR7. It induces the activation of NF-κB in HEK 293 cells expressing TLR7. |
Product Information
| Synonyms | 1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-[(ethylamino)methyl]-α,α-dimethyl-; 4-Amino-2-[(ethylamino)methyl]-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol; 1-(4-amino-2-((ethylamino)methyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol |
| IUPAC Name | 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol |
| Molecular Weight | 313.40 |
| Molecular Formula | C17H23N5O |
| Canonical SMILES | CCNCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N |
| InChI | InChI=1S/C17H23N5O/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20) |
| InChIKey | FHJATBIERQTCTN-UHFFFAOYSA-N |
| Boiling Point | 562.0±50.0°C at 760 mmHg |
| Purity | ≥98% (HPLC) |
| Density | 1.29±0.1 g/cm3 |
| Solubility | Soluble in DMSO (10 mg/mL), Water (1 mg/mL) |
| Appearance | White to beige solid powder |
| Application | Toll-Like Receptor Agonists |
| Storage | Store at -20°C |
| Complexity | 404 |
| Exact Mass | 313.19026037 |
| In Vitro | Gardiquimod (6-60 μM) significantly inhibits HIV-1 reverse transcriptase cDNA synthesis. |
| In Vivo | Dendritic cells (DCs) and Gardiquimod (1 mg/kg/mouse; i.p.; 7 days daily) in combination enhances the antitumor effect of NK cell. Result: Significant inhibition of growth of human HepG2 liver cancer xenograft tumor. |
| PSA | 88.99000 |
| Target | Toll-like Receptor (TLR); HIV |
| XLogP3-AA | 1 |
